The organs-on-chips technology is revolutionizing the field of medicine and biotechnology, offering a promising alternative to traditional animal testing and clinical trials. Organs-on-chips are microfluidic devices that mimic the structure and function of human organs, enabling researchers to simulate human physiological conditions and study drug efficacy, toxicity, and disease mechanisms in a more accurate and ethical manner.
According to a new market research report by Reports and Data, the global organs-on-chips market was valued at $21.37 million in 2020 and is projected to reach $70.87 million by 2028, growing at a CAGR of 16.3% during the forecast period (2021-2028). The report provides a comprehensive analysis of the market dynamics, trends, challenges, opportunities, competitive landscape, and regulatory framework of the organs-on-chips industry.
One of the key drivers of the organs-on-chips market growth is the increasing demand for effective and efficient drug discovery and development methods. Traditional drug development processes are time-consuming, costly, and often fail in clinical trials due to species differences and insufficient preclinical testing. Organs-on-chips offer a more streamlined and human-relevant approach to drug discovery, allowing researchers to test multiple drug candidates simultaneously and obtain more reliable results.
Another factor driving the market growth is the advancements in microfluidics and tissue engineering technologies. Microfluidics refers to the science of manipulating and controlling fluids and particles at the microscale level, while tissue engineering involves the fabrication of living tissues and organs using biomaterials and cells. Organs-on-chips combine these two technologies to create functional human organ models that can replicate the complex cellular and mechanical interactions in vivo.
The lungs-on-chips segment is expected to dominate the organs-on-chips market during the forecast period, owing to the high prevalence of respiratory diseases and the urgent need for COVID-19 research. The COVID-19 pandemic has highlighted the importance of rapid and accurate drug screening and toxicity testing, and organs-on-chips have emerged as a promising tool for studying the virus-host interactions and developing effective treatments.
However, the high cost of organs-on-chips devices and the lack of standardization and validation in the industry pose significant challenges to the market growth. Organs-on-chips are still in the early stages of commercialization, and their adoption in drug development and toxicology testing requires further validation and regulatory approval.
Nevertheless, the organs-on-chips market presents numerous opportunities for innovation and collaboration among industry players and academia. The report highlights some of the key players in the organs-on-chips market, such as Emulate, TissUse, Hurel Corporation, InSphero, Mimetas, and CN Bio Innovations, among others. These companies are actively involved in research and development, product launches, partnerships, and mergers and acquisitions to expand their product portfolio and market share.
The global organs-on-chips market is experiencing rapid growth, driven by the increasing demand for human-relevant and predictive models for drug discovery and toxicity testing. To gain a deeper understanding of the market dynamics, Reports and Data has segmented the global organs-on-chips market by type, offering, application, end user, and region.
The organs-on-chips market can be segmented into liver, kidney, lung, heart, intestines, and other organ types based on the type of organ being studied. The lungs-on-chips segment is expected to dominate the market during the forecast period, owing to the high prevalence of respiratory diseases and the urgent need for COVID-19 research. However, the liver-on-chips segment is also expected to grow at a significant rate, due to the liver’s critical role in drug metabolism and toxicity.
The market can be segmented into product and service offerings. The product segment is expected to hold the largest share of the market, as the demand for organs-on-chips devices continues to grow. However, the service segment is also expected to grow at a significant rate, as more companies offer customized organ-on-chip services to meet the specific needs of their clients.
The market can be segmented into drug discovery, toxicology research, physiological model, and other applications. The drug discovery segment is expected to hold the largest share of the market, as organs-on-chips provide a more efficient and human-relevant approach to drug discovery. However, the toxicology research segment is also expected to grow at a significant rate, as more companies and regulatory agencies recognize the potential of organs-on-chips for toxicity testing and risk assessment.
End User Outlook
The market can be segmented into pharmaceutical and biotechnology companies, academic research institutes, and other end users. The pharmaceutical and biotechnology companies segment is expected to hold the largest share of the market, as these companies are the primary users of organs-on-chips for drug discovery and development. However, the academic research institutes segment is also expected to grow at a significant rate, as more universities and research institutions adopt organs-on-chips technology for basic research and education.
The global organs-on-chips market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold the largest share of the market, due to the presence of leading organs-on-chips companies, a supportive regulatory environment, and a well-established biopharmaceutical industry. However, the Asia Pacific region is also expected to grow at a significant rate, as more companies and research institutions in the region invest in organs-on-chips technology and infrastructure.
In conclusion, the global organs-on-chips market is poised for significant growth in the coming years, driven by the increasing demand for human-relevant and predictive models for drug discovery and toxicity testing. The market presents a range of opportunities and challenges for industry players and researchers to develop innovative and validated organs-on-chips devices that can transform the way we study and treat human diseases.